Document Preview Unavailable

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With Nivolumab

Thudium, Kent; Selby, Mark; Zorn, Julie A; Rak, Gregory; Xi-Tao, Wang; et al.  bioRxiv, Jan 25, 2022.

You might have access to this document